Genfit's NASH drug fails a closely-watched PhIII showdown, adding one more setback to a plagued field
Genfit’s bid to make R&D history with a storybook turnaround came to a crashing halt on Monday as the French biotech acknowledged that its Phase III study of elafibranor failed to distinguish itself from placebo in treating NASH.
The biotech had tried to prove that the drug would resolve NASH without fibrosis in a population of more than 1,000 patients. But the data came up with a 19.2% response rate for the drug arm compared to a 14.7% rate for the placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.